Motiv8 Investments LLC Lowers Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Motiv8 Investments LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 53.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 786 shares of the company’s stock after selling 901 shares during the period. Motiv8 Investments LLC’s holdings in Eli Lilly and Company were worth $697,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Sterling Investment Advisors Ltd. raised its holdings in shares of Eli Lilly and Company by 39.3% during the 3rd quarter. Sterling Investment Advisors Ltd. now owns 925 shares of the company’s stock valued at $819,000 after buying an additional 261 shares in the last quarter. OMNI 360 Wealth Inc. grew its position in Eli Lilly and Company by 40.2% during the third quarter. OMNI 360 Wealth Inc. now owns 370 shares of the company’s stock valued at $328,000 after acquiring an additional 106 shares during the last quarter. J.W. Cole Advisors Inc. raised its stake in shares of Eli Lilly and Company by 2.2% during the third quarter. J.W. Cole Advisors Inc. now owns 9,548 shares of the company’s stock worth $8,459,000 after acquiring an additional 205 shares in the last quarter. Capital Advisors Ltd. LLC raised its stake in shares of Eli Lilly and Company by 2.0% during the third quarter. Capital Advisors Ltd. LLC now owns 1,432 shares of the company’s stock worth $1,269,000 after acquiring an additional 28 shares in the last quarter. Finally, Manchester Financial Inc. lifted its holdings in shares of Eli Lilly and Company by 4.0% in the 3rd quarter. Manchester Financial Inc. now owns 542 shares of the company’s stock worth $480,000 after acquiring an additional 21 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LLY. Citigroup lifted their target price on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday. Bank of America lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Guggenheim boosted their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Finally, Truist Financial lifted their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,013.41.

Eli Lilly and Company Price Performance

LLY stock opened at $892.70 on Monday. The firm has a 50-day moving average of $919.74 and a 200 day moving average of $863.20. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The company has a market cap of $848.43 billion, a P/E ratio of 131.47, a PEG ratio of 3.24 and a beta of 0.42. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. On average, sell-side analysts forecast that Eli Lilly and Company will post 14.05 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.